The first patients in England have been treated with Novartis’ (NOVN: VX) Luxturna (voretigene neparvovec), after the company reached a reimbursement deal in the UK in late 2019.
While the one-time therapy is listed at a cost of around £600,000 ($780,000), NHS England is reported to have agreed a confidential pricing arrangement, enabling around 100 eligible people in England to receive the treatment.
Approved in Europe in 2018, Luxturna can help people with retinal dystrophy caused by a faulty RPE65 gene.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze